On August 28, the list of the 14th Value Selection for Chinese Listed Companies, guided by the People's Daily Financial Media Group and sponsored by Securities Times, was released. Hybribio Biotech (stock code: 300639) has been listed on the “Top 50 Valued Companies Listed on ChiNext” with its steady and high-quality growth!

With the rise of A-share core assets, value investment is leading the trend again. As a benchmark for value investment, companies on the list have an excellent management team within the industry, a reputation in the capital market, a brand in the consumer market, and continued financial profitability. The characteristics of continuous improvement in investor returns, standardized information disclosure, and active performance of social responsibilities have led the long-term stable and healthy development of A-shares.

As a leading company in the field of nucleic acid testing in China, Hybribio Biotech was listed on the Growth Enterprise Market of the Shenzhen Stock Exchange in 2017. After nearly 20 years of development, based on the flow-through hybridization technology platform with independent intellectual property rights and the internationally universal fluorescent PCR detection technology platform, nucleic acid detection reagents and supporting facilities covering the fields of infectious and genetic diseases such as reproductive tract infections and birth defects have been developed . The equipment and products cover 1,800 domestic hospital networks and are sold to more than 30 countries and regions at home and abroad.

At the same time, relying on the technologies, products, customers, channels, talents and other resources that have been established for years of deep cultivation of nucleic acid molecular diagnosis, it extends to the downstream of the industrial chain, focuses on expanding third-party medical inspection business, and establishes 25 third-party medical laboratories in many key cities , which built the inspection service network  across the country and provide medical institutions with high-end, accurate, standardized, and cutting-edge medical inspection services.

In 2019, the annual operating income reached 729 million yuan, a year-on-year increase of 25.68%, and the net profit attributable to shareholders of listed companies was 147 million yuan, a year-on-year increase of 29.11%; in 2020, the operating income in the first half of the year reached 506 million yuan, a year-on-year increase of 59.44%. The net profit attributable to shareholders of listed companies was 129 million yuan, a year-on-year increase of 115.43%. With the national medical and health industry policy guidance and customer needs, Hybribio’s product matrix, customer resources, and sales network accumulated over the years in the field of nucleic acid detection reagents have laid a solid foundation for the rapid development of business in each segment. Hybribio is gradually increasing its market share and become a value-growing enterprise with steady growth.

This time, Hybribio Biotech was awarded the "Top 50 Listed Companies on the Chinese Growth Enterprise Market in Value", which is a high recognition of the company's leading position and comprehensive strength by the Chinese capital market and the majority of investors, and it is also a recognition of Hybribio 's efforts in the field of nucleic acid testing and molecular inspection industry for many years. In the future, Hybribio will continue to build its own competitive advantages in R&D innovation and product reserve, in brand building, in the network of sales and service , in product quality and capacity building, in product + service integrated business model. This will promote the company's performance to achieve steady growth and create more value for society, industry, shareholders and employees!

List of top 50 valued companies listed on GEM